Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2/3 1Phase 2 1Phase 1 1

Status

Recruiting 59Unknown 36Active not recruiting 13Terminated 8Not yet recruiting 7Completed 6Withdrawn 4Available 1

Sponsor Class

OTHER 6

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Dermatologic 2Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Gastrointestinal 1

Conditions

Neoplasms 2Melanoma 2Pelvic Neoplasms 1Neoplasm Metastasis 1Lymphoma, B-Cell 1Leukemia, B-Cell 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 1495Cisplatin 1431Paclitaxel 1339Radiotherapy 1308Carboplatin 1264Gemcitabine 1225Docetaxel 1134Bevacizumab 1068Fluorouracil 906Doxorubicin 799Dexamethasone 753Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 693Etoposide 674Irinotecan 639Filgrastim 624Nivolumab 585Cytarabine 585Leucovorin 582Vincristine 512Cetuximab 478Prednisone 477Bortezomib 472Trastuzumab 469Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 443Lenalidomide 434

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × Immunotherapy, Adoptive × Clear all
NCT03757858 2024-02-07

Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases

Capital Medical University

Phase 1/2 Completed
40 enrolled
Gynecologic

Neoplasm Metastasis, Neoplasms, Pelvic Neoplasms

NCT04279470 2023-04-13

CARTABLE

Groupe Hospitalier Pitie-Salpetriere

Completed
100,000 enrolled

Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT03068416 2021-10-20

CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy

Uppsala University

Phase 2 Completed
24 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Lymphoma, B-Cell

NCT02851784 2021-03-04

Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma

Chinese PLA General Hospital

Phase 2/3 Completed
40 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT02354690 2020-03-23

Vemurafenib and TIL Therapy for Metastatic Melanoma

Herlev Hospital

Phase 1/2 Completed
13 enrolled 12 charts
Dermatologic

Melanoma

NCT00324623 2012-11-20

Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma

Centre Hospitalier Universitaire Vaudois

Phase 1 Completed
8 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡